Show simple item record

 

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCho, Byoung Chul
dc.contributor.authorGoto, Koichi
dc.contributor.authorJohnson, Melissa
dc.contributor.authorGaron, Edward
dc.contributor.authorFELIP, ENRIQUETA
dc.contributor.authorSpira, Alexander
dc.date.accessioned2025-03-12T08:06:48Z
dc.date.available2025-03-12T08:06:48Z
dc.date.issued2025-01
dc.identifier.citationSpira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, et al. FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer. 2025 Jan;199:108066.
dc.identifier.issn0169-5002
dc.identifier.urihttp://hdl.handle.net/11351/12749
dc.descriptionFirmonertinib; Furmonertinib; Metastatic
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesLung Cancer;199
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectPulmons - Càncer - Aspectes genètics
dc.subjectProteïnes quinases - Inhibidors - Ús terapèutic
dc.subjectReceptors cel·lulars
dc.subjectAnomalies cromosòmiques
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshMutation
dc.subject.meshProtein Kinase Inhibitors
dc.subject.mesh/therapeutic use
dc.subject.meshReceptor, ErbB-2
dc.titleFURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.lungcan.2024.108066
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsmutación
dc.subject.decsinhibidores de proteínas cinasas
dc.subject.decs/uso terapéutico
dc.subject.decsreceptores ErbB
dc.relation.publishversionhttps://doi.org/10.1016/j.lungcan.2024.108066
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Spira A] Virginia Cancer Specialists Research Institute and Next Oncology, Fairfax, VA, United States. [Cho BC] Division of Medical Oncology, Yonsei Cancer Center, Yonsei University of Medicine, Seoul, Republic of Korea. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Garon EB] David Geffen School of Medicine, Division of Hematology and Oncology, UCLA, Los Angeles, CA, United States. [Goto K] National Cancer Center Hospital East, Kashiwa, Japan. [Johnson M] Sarah Cannon Research Institute, Nashville, TN, United States
dc.identifier.pmid39764938
dc.identifier.wos001398449200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Name:
furvent-phase-3-trial-firmoner ...
Size:
822.9Kb
Format:
PDF
Description:
FURVENT: Phase 3 trial of ...
View

This item appears in the following Collection(s)

Show simple item record